Institutional Biosafety/recombinant DNA Committee (IBC) Charter
- The University of Texas at El Paso (UTEP) follows the National Institutes of Health (NIH) system for enhancing science through safety and ethics of recombinant or synthetic nucleic acid (rDNA) research. The responsibility of NIH oversight of rDNA research lies with the NIH Office of Science Policy (OSP). UTEP uses the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, the Institutional Biosafety Committee (IBC), and the NIH Recombinant DNA Advisory Committee (RAC) as key tools for biosafety and rDNA research oversight. The NIH Guidelines are intended to assist UTEP, the IBC, the Biological Safety Officer (BSO), and the Principal Investigators (PI) in determining the safeguards that must be implemented to conduct rDNA research. This document outlines the responsibilities and procedures that the UTEP IBC uses to implement, promote and manage safe, and ethical rDNA research at UTEP.
Research covered by this policy will fall into one of the following four categories.
- rDNA (Recombinant or synthetic nucleic acids):
• Molecules that are constructed outside living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell;
• Molecules that replicate as a result of the above.
- RG2 (Risk Group 2): Agents that are associated with diseases that are rarely serious and for which preventive/therapeutic interventions are often available
- RG3 (Risk Group 3): Agents that are associated with serious/lethal human diseases for which preventive/therapeutic interventions may be available (high individual risk, but low community risk)
- RG4 (Risk Group 4): Agents that are likely to cause serious/lethal human diseases for which preventive/therapeutic interventions are not usually available (high individual risk and high community risk)
V. IBC Policies and Procedures
VI. Protocol Review Process